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ABSTRACT
Here, we used an informatics-based approach to identify novel biomarkers of 
overall survival and tumor progression in non-small cell lung cancer (NSCLC) patients. 
We determined whether nuclear-encoded genes associated with mitochondrial 
biogenesis and function can be used to effectively predict clinical outcome in lung 
cancer. This strategy allowed us to directly provide in silico validation of the prognostic 
value of these mitochondrial components in large, clinically-relevant, lung cancer 
patient populations. Towards this end, we used a group of 726 lung cancer patients, 
with negative surgical margins. Importantly, in this group of cancer patients, markers 
of cell proliferation (Ki67 and PCNA) were associated with poor overall survival, 
as would be expected. Similarly, key markers of inflammation (CD163 and CD68) 
also predicted poor clinical outcome in this patient population. Using this approach, 
we identified >180 new individual mitochondrial gene probes that effectively 
predicted significantly reduced overall survival, with hazard-ratios (HR) of up to 
4.89 (p<1.0e-16). These nuclear-encoded mitochondrial genes included chaperones, 
membrane proteins as well as ribosomal proteins (MRPs) and components of the 
OXPHOS (I-V) complexes. In this analysis, HSPD1, a key marker of mitochondrial 
biogenesis, had the highest predictive value and was also effective in predicting 
tumor progression in both smokers and non-smokers alike. In fact, it had even higher 
predictive value in non-smokers (HR=5.9; p=3.9e-07). Based on this analysis, we 
conclude that mitochondrial biogenesis should be considered as a new therapeutic 
target, for the more effective treatment of human lung cancers. The mitochondrial 
biomarkers that we have identified could serve as new companion diagnostics to assist 
clinicians in more accurately predicting clinical outcomes in lung cancer patients, 
driving more personalized cancer therapy.
INTRODUCTION
Treatment failure is the most critical obstacle for 
more effective anti-cancer therapy and personalized 
medicine [1, 2]. As such, this still dramatically limits the 
efficacy of most cancer treatments, especially in lung 
cancer patients. As a consequence, better biomarkers are 
needed for the early stratification of lung cancer patients 
into low-risk and high-risk groups at diagnosis [1-3]. 
Here, we examined the hypothesis that markers 
of mitochondrial biogenesis and function may have 
significant prognostic value in the early identification of 
high-risk lung cancer patients, with poor overall clinical 
survival and tumor progression. In this context, we 
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employed a bioinformatics approach to assess the possible 
utility of nuclear-encoded mitochondrial gene transcripts 
in predicting clinical outcome. 
Our results indicate that > 180 different 
mitochondrial gene probes can be used individually, to 
predict poor overall survival in lung cancer patients. As 
such, we discuss the possibility that mitochondria should 
be therapeutically targeted, to improve the effectiveness of 
current lung cancer therapy and overall survival. 
RESULTS
Value of proliferative and inflammatory markers 
in the patient population
To identify new potential biomarkers, here we used 
publically available transcriptional profiling data from 
the tumors of lung cancer patients, with negative surgical 
margins (Figure 1), with 10 years of follow-up. Since 
proliferative markers are used as primary endpoints in 
clinical trials, we first assessed the prognostic value of 
Ki67 and PCNA, in this patient population. Tables 1, 2 
and Figure 2A both show the prognostic value of these 
markers. The hazard-ratios for Ki67 and PCNA were 4.85 
and 1.82, respectively, for overall survival (OS). 
We also assessed the prognostic value of two 
macrophage-specific markers of inflammation. Table 
2 and Figure 2B show that CD163 and CD68 both 
effectively predict overall survival, with hazard-ratios of 
1.95 and 1.59, respectively. Thus, conventional markers 
of proliferation and inflammation can be used to predict 
overall survival in lung cancer patients
Value of individual mitochondrial markers
To test our hypothesis that increased mitochondrial 
mass, biogenesis and function contributes towards poor 
overall survival in lung cancer patients, we next assessed 
the prognostic value of specific mitochondrial markers. 
Initially, we examined the behavior of mitochondrial 
chaperones and mitochondrial membrane proteins. Table 3 
and Figure 3 both show that HSP60 (HSPD1) has the best 
prognostic value, with a hazard-ratio of 4.89 (p < 1.0e-
17). Members of the TIMM and TOMM gene families 
also had prognostic value; AKAP1 and SLC25A5 also 
had significant value. Similar results were also obtained 
with mitochondrial creatine kinase isoforms (HR = 2.88-
to-1.51) and PRKDC (DNA-PK), a critical kinase that 
helps maintain the integrity and the copy number of the 
mitochondrial genome (mt-DNA) (HR = 4.69-to-1.65), 
which functions in the DNA damage response. 
Secondly, we examined the prognostic value 
of mitochondrial ribosomal proteins (MRPs), which 
contribute to the synthesis of key members of the 
OXPHOS-complexes, and are essential for mitochondrial 
biogenesis (Table 4). Twenty-one components of the 
large subunit (MRPLs) showed significant prognostic 
value, with hazard-ratios between 4.36 and 1.47. Notably, 
MRPL48 had the best prognostic value. Fifteen different 
components of the small subunit (MRPSs) showed 
significant prognostic value, with hazard-ratios between 
4.10 and 1.27. As such, thirty-six different MRPs all 
predicted poor overall survival. Kaplan-Meier curves for 
representative examples are shown in Figure 4, panels A 
& B.
We also assessed the prognostic value of members 
of the OXPHOS complexes I-V. These results are 
summarized in Table 5. Remarkably, 88 different gene 
probes for the OXPHOS complexes showed hazard-ratios 
between 4.46 and 1.39. COX5B (complex IV) had the 
best prognostic value (HR = 4.46; p = 5.3e-15). NDUFB3 
(complex I) also showed significant prognostic value (HR 
= 4.30; p = 3.6e-15). Kaplan-Meier curves for members 
of complex I and II are shown in Figure 5A & 5B, while 
results with members of complex III and IV are shown in 
Figure 6A & 6B. Results with complex V are shown in 
Figure 7.
Mitochondrial genes have predictive value in 
both “smoking” and “non-smoking” patient 
populations: overall survival and tumor 
progression
In order to further test the prognostic power of these 
individual mitochondrial biomarkers, we next selected the 
most promising one, HSPD1, and assessed its ability to 
predict tumor progression in the whole patient population 
(N = 726). Importantly, Figure 8 shows that the levels of 
HSPD1 effectively predict time to tumor progression and 
post-progression survival, with hazard ratios of 3.28 and 
1.88, respectively. 
A similar analysis was also carried out when the 
patient population was sub-divided into smokers (N 
= 464) and non-smokers (N = 160) (Figures 9 and 10). 
Using this approach, HSPD1 showed increased prognostic 
power in the non-smoking patient population, reaching a 
hazard-ratio of 5.9 for overall survival; however, HSPD1 
still retained its prognostic value in the smoking patient 
population (Figures 9A and 10A).
In this context, this trend was also true for tumor 
progression, as HSPD1 was a better predictor of time to 
tumor progression and post-progression survival in non-
smokers (Figures 9B and 10B), with hazard-ratios of 3.64 
and 2.89, respectively. 
Thus, the mitochondrial chaperone, HSPD1, is an 
effective predictive biomarker of overall survival and 
tumor progression, in both smokers and non-smokers as 
well. 
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Figure 2: Markers of proliferation and inflammation predict poor overall survival in high-risk lung cancer patients. 
We assessed the predictive value of Ki67 and PCNA in N = 726 lung cancer patients, with negative surgical margins. A. Note that high 
transcript levels of Ki67 and PCNA are associated with significantly reduced overall survival. Please note that the official gene name for 
the Ki67 protein is MKI67. B. Note that that high transcript levels of CD163 and CD68 are associated with significantly reduced overall 
survival.
Figure 1: Diagram showing our bio-informatics approach to lung cancer biomarker discovery. For this analysis, we chose 
to focus on non-small lung cancer patients, with negative surgical margins, and 10-years of follow-up data (N = 726). In this context, we 
evaluated the prognostic value of mitochondrial markers for predicting overall survival, time to first progression, and post-progression 
survival. 
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Figure 3: HSPD1, mitochondrial membrane proteins and PRKDC are associated with poor clinical outcome in lung 
cancer patients. A. Note that that high transcript levels of HSPD1 and TIMM23 are associated with significantly reduced overall 
survival. B. Note that that high transcript levels of PRKDC are associated with significantly reduced overall survival.
Table 1: Prognostic Value of KI67 in Lung Cancer
Table 2: Prognostic Value of PCNA and Markers of Inflammation in Lung Cancer
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Figure 4: Mitochondrial ribosomal proteins (MRPs) are associated with poor clinical outcome in lung cancer patients. 
A. Note that high transcript levels of MRPL48 and MRPL23 predict significantly reduced overall survival. B. Similarly, high transcript 
levels of MRPS12 and MRPS7 predict significantly reduced overall survival. 
Figure 5: Mitochondrial complex I and II proteins are associated with poor clinical outcome in lung cancer patients. 
A. Note that high levels of NDUFB3 and NDUFS8 predict significantly reduced overall survival. B. Similarly, high levels of SDHC and 
SDHB predict significantly reduced overall survival. 
Oncotarget68100www.impactjournals.com/oncotarget
Figure 7: Mitochondrial complex V proteins are associated with poor clinical outcome in lung cancer patients. Note that 
high levels of ATP5J2 and ATP5G3 predict significantly reduced overall survival. 
Figure 6: Mitochondrial complex III and IV proteins are associated with poor clinical outcome in lung cancer patients. 
A. Note that high levels of UQCR7 and UQCR6 predict significantly reduced overall survival. B. Similarly, high levels of COX5B and 
COX6A predict significantly reduced overall survival. 
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Figure 8: The mitochondrial chaperone, HSPD1, predicts tumor progression in lung cancer patients. Note that the levels 
HSPD1 effectively predict time to first progression (Left panel) and post-progression survival (Right panel).
Figure 9: The mitochondrial chaperone, HSPD1, predicts poor clinical outcome and tumor progression in lung cancer 
patients: Smokers. Note that the levels HSPD1 effectively predict overall survival A., as well as time to first progression and post-
progression survival B., in the “smoking” patient population.
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DISCUSSION
Linking CSC propagation with telomerase 
activity and mitochondrial function: Targeting 
CSCs with doxycycline and/or palbociclib
Recently, we determined the functional role of 
telomerase activity in lung cancer stem cell (CSC) 
propagation. More specifically, we indirectly monitored 
telomerase activity, by linking the hTERT-promoter 
to eGFP [4, 5]. Using A549 lung cancer cells, stably-
transfected with the hTERT-GFP reporter, we then used 
GFP-expression fluorescence intensity to fractionate these 
cell lines into GFP-high and GFP-low cell populations. 
We functionally compared the phenotype of these GFP-
high and GFP-low cell sub-populations. Importantly, 
we directly demonstrated that cancer cells with higher 
telomerase activity (GFP-high) are energetically-activated, 
with increased mitochondrial function and increased 
glycolysis. This was directly confirmed by proteomics 
Table 3: Prognostic Value of Mitochondrial HSPs and Other Mitochondrial Proteins
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analysis. Cells with high telomerase activity showed 
increased stem cell activity (measured via 3D-spheroid 
formation) and an increased capacity for cell migration 
(measured with a Boyden-chamber). These phenotypes 
were blocked by inhibitors of energy-metabolism, which 
targeted either mitochondrial OXPHOS or glycolysis, or 
by using doxycycline, an FDA-approved antibiotic, that 
inhibits mitochondrial biogenesis as an off-target effect [4, 
5].
The levels of telomerase activity also determined 
the ability of hTERT-high CSCs to proliferate, as 
assessed by measuring DNA synthesis [4, 5]. Treatment 
with Palbociclib, an FDA-approved CDK4/6 inhibitor 
specifically blocked the propagation of lung CSCs, 
at concentrations in the nanomolar range. Therefore, 
telomerase-high CSCs are among the most energetically 
Table 4: Prognostic Value of Mitochondrial Ribosomal Proteins
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Table 5: Prognostic Value of Mitochondrial OXPHOS Complexes
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activated, migratory and proliferative cell sub-populations. 
These observations may provide a mechanistic explanation 
for why long telomere length [6-9] (a surrogate marker of 
increased telomerase activity) is specifically associated 
with metastasis and poor clinical outcome in NSC lung 
cancer and many other tumor types. Thus, high telomerase 
activity may drive poor clinical outcome by activating 
mitochondrial biogenesis, “fueling” the proliferation in 
lung CSCs [4, 5].
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Using mitochondrial markers as companion 
diagnostics in NSCLC patients: Importance for 
treatment stratification and personalized medicine
Consistent with this novel hypothesis linking 
high telomerase activity with enhanced mitochondrial 
function, we show here that mitochondrial markers 
effectively predict poor overall survival in lung cancer 
patients, with negative surgical margins. Importantly, 
these mitochondrial markers could now be used to identify 
high-risk lung cancer patients at diagnosis, up to 10 years 
in advance. These results also suggest that mitochondria 
should be therapeutically-targeted in epithelial lung cancer 
cells to significantly extend patient survival. 
In this workflow, high-risk patients should be 
first identified at diagnosis by the high expression of 
mitochondrial markers in their primary lung tumors 
(Figure 11). Then, these patients could be treated with 
FDA-approved therapeutics (e.g., Doxycycline or 
Palbociclib; in combination with the standard of care), to 
improve poor overall survival. Importantly, both of these 
drugs have already been shown to be effective against the 
propagation of the lung CSC sub-population. 
In this context, these mitochondrial markers could 
also be used as effective companion diagnostics for new 
experimental therapeutics targeting either mitochondria or 
telomerase (hTERT) and/or cell proliferation, to select the 
high-risk lung cancer patient sub-group, allowing proper 
Figure 10: The mitochondrial chaperone, HSPD1, predicts poor clinical outcome and tumor progression in lung 
cancer patients: Non-Smokers. Note that the levels HSPD1 effectively predict overall survival A., as well as time to first progression 
and post-progression survival B., in the “non-smoking” patient population.
Figure 11: NSC lung cancer: mitochondrial-based 
diagnostics for personalized cancer therapy. In this 
diagram, mitochondrial-based diagnostics would be used to 
separate lung cancer patients into high-risk and low-risk groups. 
Then, patients with high levels of mitochondrial markers in 
their primary tumor (“bad prognosis”) would be treated with 
mitochondrial-based therapies (such as “Doxycycline”), as an 
add-on to the standard of care, to prevent tumor progression and 
increase overall survival.
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treatment stratification. 
MATERIALS AND METHODS
Kaplan-Meier (K-M) analyses
To perform K-M analysis on nuclear mitochondrial 
gene transcripts, we used an open-access online survival 
analysis tool to interrogate publically available microarray 
data from up to 1,926 lung cancer patients [3]. This 
allowed us to determine their overall prognostic value. 
For this purpose, we primarily analyzed 10-year follow-
up data from non-small cell lung cancer (NSCLC) patients 
that had negative surgical margins (N = 726) [3]. Biased 
array data were excluded from the analysis. This allowed 
us to identify > 180 nuclear mitochondrial gene probes, 
with significant prognostic value. Hazard-ratios were 
calculated, at the best auto-selected cut-off, and p-values 
were calculated using the logrank test and plotted in R. 
K-M curves were also generated online using the K-M-
plotter (as high-resolution TIFF files), using univariate 
analysis: 
http://kmplot.com/analysis/index.php?p = 
service&cancer = lung. 
This allowed us to directly perform in silico 
validation of these mitochondrial biomarker candidates. 
The most updated version of the database (2015) was 
utilized for all these analyses.
Abbreviations
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